HanchorBio Inc.

HanchorBio Inc. is a biotechnology company established in 2020 and headquartered in Taipei, Taiwan. Specializing in immuno-oncology, HanchorBio is dedicated to developing next-generation biologic therapies designed to enhance and harness the immune system's ability to combat cancer. The company's core innovation lies in its proprietary Fc-Based Designer Biologics (FBDB™) technology platform, which engineers multifunctional molecules capable of simultaneously activating both innate and adaptive immune responses to target and eliminate tumors. HanchorBio's pipeline features advanced therapeutic candidates, including HCB101—a CD47-targeting fusion protein—highlighted by recent progress into Phase 2 clinical trials across Taiwan, the United States, and China. The company operates globally with a growing presence in the United States, mainland China, and Taiwan, supported by a leadership team recognized for deep experience in biologics research and regulatory success. Through strategic partnerships and robust investment from prominent institutional investors, HanchorBio positions itself as a significant innovator within the biotechnology and pharmaceutical sectors, working to address unmet medical needs in oncology and contribute to advancements in precision immunotherapy.